Absentia Labs: Turning a First-of-Its-Kind FDA Milestone Into National Coverage
Client: Absentia Labs
The Challenge
Absentia Labs, a Boston biotech founded in 2024, needed to translate a deeply technical AI and drug-safety milestone into a credible national story — announcing that its Digital Liver Model had become the first-of-its-kind AI-enabled in silico Drug Development Tool accepted into the FDA’s ISTAND qualification pathway, in a category where scientific rigor and regulatory nuance both had to come through clearly to press and industry audiences alike.
Our Approach
We developed the launch narrative and key messages, positioned Absentia’s MIT-trained founding team as credible spokespeople, and built a national media strategy targeting technology, business, biotech, and drug-development trade press. We paired the FDA milestone with Absentia’s recognition as a winner of the FDA’s own precisionFDA Predictive Modeling of Hepatotoxicity Challenge, reinforcing the story with third-party validation.
Coverage & Recognition
The FDA milestone announcement secured nationwide broadcast and news pickup across dozens of U.S. outlets, including BioSpace, alongside regional broadcast affiliates spanning New York, Michigan, Iowa, South Dakota, and beyond.
The story was paired with Absentia's recognition as a winner of the FDA's own precisionFDA Predictive Modeling of Hepatotoxicity Challenge, reinforcing the announcement with third-party regulatory validation.